• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Correction to: Indirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021-2023.

作者信息

Igarashi Ataru, Tanaka Shiro, De Moor Raf, Li Nan, Hirozane Mariko, Wu David Bin-Chia, Hong Li Wen, Yu Dae Young, Hashim Mahmoud, Hutton Brian, Tantakoun Krista, Olsen Christopher, Fashami Fatemeh Mirzayeh, Samjoo Imtiaz A, Cameron Chris

机构信息

Unit of Public Health and Preventive Medicine, Yokohama City University School of Medicine, Kanazawa Ward, Yokohama, Kanagawa, Japan.

Graduate School of Medicine, Kyoto University, Kyoto, Japan.

出版信息

Adv Ther. 2025 Jan;42(1):70-71. doi: 10.1007/s12325-024-03087-2.

DOI:10.1007/s12325-024-03087-2
PMID:39760977
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11782334/
Abstract
摘要

相似文献

1
Correction to: Indirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021-2023.对《医疗保健决策中的间接治疗比较：2021 - 2023年全球肿瘤药物监管批准、报销和定价建议的针对性综述》的勘误
Adv Ther. 2025 Jan;42(1):70-71. doi: 10.1007/s12325-024-03087-2.
2
Indirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021-2023.医疗决策中的间接治疗比较：2021 - 2023年全球肿瘤药物监管批准、报销和定价建议的针对性综述
Adv Ther. 2025 Jan;42(1):52-69. doi: 10.1007/s12325-024-03013-6. Epub 2024 Nov 12.
3
The reimbursement decision speed for oncology new drugs in China and its determinant factors.中国肿瘤新药的报销决策速度及其决定因素。
Front Public Health. 2023 Oct 30;11:1207739. doi: 10.3389/fpubh.2023.1207739. eCollection 2023.
4
Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019.治疗定位报告在西班牙 P&R 流程中的影响：对欧洲委员会批准并于 2003 年至 2019 年在西班牙报销的孤儿药的分析。
Orphanet J Rare Dis. 2020 Aug 28;15(1):224. doi: 10.1186/s13023-020-01507-4.
5
Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021.2019 年至 2021 年监管批准状况对 CADTH 肿瘤药物报销的影响以及真实世界证据对有条件批准的作用。
Curr Oncol. 2022 Oct 26;29(11):8031-8042. doi: 10.3390/curroncol29110635.
6
Balancing early access with uncertainties in evidence for drugs authorized by prospective case series - systematic review of reimbursement decisions.平衡前瞻性病例系列授权药物证据中的不确定性与早期获取 - 报销决策的系统评价。
Br J Clin Pharmacol. 2018 Jun;84(6):1146-1155. doi: 10.1111/bcp.13531. Epub 2018 Mar 23.
7
Analysing criteria for price and reimbursement of orphan drugs in Spain.西班牙罕见病药物的定价与报销分析标准
Farm Hosp. 2019 Jul 1;43(4):121-127. doi: 10.7399/fh.11147.
8
The merry-go-round of approval, pricing and reimbursement of drugs against the Hepatitis C virus infection in Spain.
Health Policy. 2016 Sep;120(9):975-81. doi: 10.1016/j.healthpol.2016.07.005. Epub 2016 Jul 16.
9
Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement.中国创新药物准入与国家医保药品目录：定价与报销的动态变化及未来趋势
J Mark Access Health Policy. 2023 Jun 13;11(1):2218633. doi: 10.1080/20016689.2023.2218633. eCollection 2023.
10
Drug pricing and reimbursement information management: processes and decision making in the global economy.药品定价与报销信息管理：全球经济中的流程与决策
J Mark Access Health Policy. 2017 Jun 30;5(1):1340747. doi: 10.1080/20016689.2017.1340747. eCollection 2017.